TY - JOUR
T1 - Should asymptomatic progression following definitive local treatment for prostate cancer be treated?
AU - Lillis, P.
AU - Thompson, I. M.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - Asymptomatic progression following definitive therapy for prostate cancer can take the form of a detectable prostate-specific antigen (PSA) or local recurrence following radical prostatectomy or a rising PSA or palpable recurrence following radiotherapy. Options for treatment include hormonal therapy, radiotherapy, salvage surgery, and experimental therapies. Although such forms of treatment have known effects on intermediate endpoints, such as reduction of PSA, the overall effect on survival and quality of life is uncertain.
AB - Asymptomatic progression following definitive therapy for prostate cancer can take the form of a detectable prostate-specific antigen (PSA) or local recurrence following radical prostatectomy or a rising PSA or palpable recurrence following radiotherapy. Options for treatment include hormonal therapy, radiotherapy, salvage surgery, and experimental therapies. Although such forms of treatment have known effects on intermediate endpoints, such as reduction of PSA, the overall effect on survival and quality of life is uncertain.
UR - http://www.scopus.com/inward/record.url?scp=0030014821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030014821&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(05)70362-2
DO - 10.1016/S0889-8588(05)70362-2
M3 - Article
C2 - 8773506
AN - SCOPUS:0030014821
SN - 0889-8588
VL - 10
SP - 703
EP - 712
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 3
ER -